rapacuronium
Trade name: Raplon
Approved
Aug 18, 1999
Rapacuronium bromide (RAPLON), a nondepolarizing neuromuscular blocking agent, is a negative allosteric modulator of muscarinic acetylcholine receptors. Rapacuronium bromide is indicated as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgical procedures. There were no specific pharmacokinetic studies conducted to examine the drug-drug interactions of RAPLON. Due to the risk of fatal bronchospasm, it was withdrawn from the United States market less than 2 years after its FDA approval. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Timeline
Indications
Approved for
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
non-depolarizing
Approval history
- approvedAug 18, 1999
Chemistry & pharmacology
SMILES
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](OC(C)=O)[C@@H](N6CCCCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(=O)CC)CCCCC1- Mol. weight
- 597.91 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1201352 ↗
- WikipediaRapacuronium bromide ↗
- NCATS65Q4QDG4KC ↗
- ChEMBLCHEMBL1200549 ↗
Also known as
- org9487
- org 9487
- org 9487
- org-9487
- org-9487
- org-9487
- org-9487
- org-9487
- org-9487
- rapacuronium
- rapacuronium
- rapacuronium
- rapacuronium
- rapacuronium
- rapacuronium
- rapacuronium
- rapacuronium
- rapacuronium bromide
- rapacuronium bromide
- rapacuronium bromide
- rapacuronium bromide
- rapacuronium bromide
- raplon
- raplon
- raplon
- raplon
- raplon